Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2549-2567

  Viayna, Elisabet ^a,f   Sola, Irene ^a   Bartolini, Manuela ^b   De Simone, Angela ^b   Tapia Rojas, Cheril ^c   Serrano, Felipe G ^c   Sabaté, Raimon ^a,d   Juárez Jiménez, Jordi ^a   Pérez, Belén ^e   Luque, F Javier ^a   Andrisano, Vincenza ^b   Clos, M Victòria ^e   Inestrosa, Nibaldo C ^c   Muñoz Torrero, Diego ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUT DE NEUROCIÈNCIES   (Spain)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; N [9 [(3 CHLORO 6,7,10,11 TETRAHYDRO 9 METHYL 7,11 METHANOCYCLOOCTA[B]QUINOLIN 12 YL)AMINO]NONYL] 9,10 DIHYDRO 4,5 DIHYDROXY 9,10 DIOXOANTHRACENE 2 CARBOXAMIDE; RHEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DRUG SYNTHESIS; DRUG TARGETING; ESCHERICHIA COLI; EX VIVO STUDY; HUMAN; MOUSE; NONHUMAN; TRANSGENIC MOUSE; TREATMENT DURATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTHRAQUINONES; ASPARTIC ACID ENDOPEPTIDASES; BINDING SITES; BLOOD-BRAIN BARRIER; CHOLINESTERASE INHIBITORS; ENZYME INHIBITORS; ESCHERICHIA COLI; HIPPOCAMPUS; HUMANS; KINETICS; LONG-TERM POTENTIATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; STEREOISOMERISM; SYNAPSES; TAU PROTEINS;

EID: 84897436396     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401824w     Document Type: Article

References (105)

1. Batsch, N. L.; Mittelman, M. S. World Alzheimer Report 2012. Overcoming the Stigma of Dementia; Alzheimer's Disease International: London, 2012; http://www.alz.co.uk.
2. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 2002, 297, 353-356
3. Kung, H. F. The β-amyloid hypothesis in Alzheimer's disease: seeing is believing ACS Med. Chem. Lett. 2012, 3, 265-267
4. Citron, M. Alzheimer's disease: strategies for disease modification Nature Rev. Drug Discovery 2010, 9, 387-398
5. Pimplikar, S. W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease Int. J. Biochem. Cell Biol. 2009, 41, 1261-1268
6. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
7. Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B. Multi-target-directed ligands in Alzheimer's disease treatment Curr. Med. Chem. 2011, 18, 4949-4975
8. Geldenhuys, W. J.; Van der Schyf, C. J. Rationally designed multi-targeted agents against neurodegenerative diseases Curr. Med. Chem. 2013, 20, 1662-1672
9. Chen, X.; Decker, M. Multi-target compounds acting in the central nervous system designed from natural products Curr. Med. Chem. 2013, 20, 1673-1685
10. Russo, P.; Frustaci, A.; Del Bufalo, A.; Fini, M.; Cesario, A. Multitarget drugs of plants origin acting on Alzheimer's disease Curr. Med. Chem. 2013, 20, 1686-1693
11. For recent examples, see refs 11-15. Butini, S.; Brindisi, M.; Brogi, S.; Maramai, S.; Guarino, E.; Panico, A.; Saxena, A.; Chauhan, V.; Colombo, R.; Verga, L.; De Lorenzi, E.; Bartolini, M.; Andrisano, V.; Novellino, E.; Campiani, G.; Gemma, S. Multifunctional cholinesterase and amyloid beta fibrillization modulators. Synthesis and biological investigation. ACS Med. Chem. Lett. 2013, 4, 1178-1182.
12. Capurro, V.; Busquet, P.; Lopes, J. P.; Bertorelli, R.; Tarozzo, G.; Bolognesi, M. L.; Piomelli, D.; Reggiani, A.; Cavalli, A. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease PLoS One 2013, 8, e56870
13. Kochi, A.; Eckroat, T. J.; Green, K. D.; Mayhoub, A. S.; Lim, M. H.; Garneau-Tsodikova, S. A novel hybrid of 6-chlorotacrine and metal-amyloid-β modulator for inhibition of acetylcholinesterase and metal-induced amyloid-β aggregation Chem. Sci. 2013, 4, 4137-4145
14. Xie, S.-S.; Wang, X.-B.; Li, J.-Y.; Yang, L.; Kong, L.-Y. Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease Eur. J. Med. Chem. 2013, 64, 540-553
15. Prinz, M.; Parlar, S.; Bayraktar, G.; Alptüzün, V.; Erciyas, E.; Fallarero, A.; Karlsson, D.; Vuorela, P.; Burek, M.; Förster, C.; Turunc, E.; Armagan, G.; Yalcin, A.; Schiller, C.; Leuner, K.; Krug, M.; Sotriffer, C. A.; Holzgrabe, U. 1,4-Substituted 4-(1 H)-pyridylene-hydrazone- type inhibitors of AChE, BChE, and amyloid-β aggregation crossing the blood-brain barrier Eur. J. Pharm. Sci. 2013, 49, 603-613
16. Viayna, E.; Sabate, R.; Muñoz-Torrero, D. Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates Curr. Top. Med. Chem. 2013, 13, 1820-1842
17. Inestrosa, N. C.; Alvarez, A.; Pérez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme Neuron 1996, 16, 881-891
18. Alvarez, A.; Alarcón, R.; Opazo, C.; Campos, E. O.; Muñoz, F. J.; Calderón, F. H.; Dajas, F.; Gentry, M. K.; Doctor, B. P.; De Mello, F. G.; Inestrosa, N. C. Stable complexes involving acetylcholinesterase and amyloid-β-peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils J. Neurosci. 1998, 18, 3213-3223
19. De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation Biochemistry 2001, 40, 10447-10457
20. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein Science 1991, 253, 872-879
21. Du, D.-M.; Carlier, P. R. Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease Curr. Pharm. Des. 2004, 10, 3141-3156
22. Recanatini, M.; Valenti, P. Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics Curr. Pharm. Des. 2004, 10, 3157-3166
23. Castro, A.; Martinez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors Curr. Pharm. Des. 2006, 12, 4377-4387
24. Li, W. M.; Kan, K. K. W.; Carlier, P. R.; Pang, Y. P.; Han, Y. F. East meets West in the search for Alzheimer's therapeutics-novel dimeric inhibitors from tacrine and huperzine A Curr. Alzheimer Res. 2007, 4, 386-396
25. Holzgrabe, U.; Kapková, P.; Alptüzün, V.; Scheiber, J.; Kugelmann, E. Targeting acetylcholinesterase to treat neurodegeneration Expert Opin. Ther. Targets 2007, 11, 161-179
26. Musial, A.; Bajda, M.; Malawska, B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment Curr. Med. Chem. 2007, 14, 2654-2679
27. Haviv, H.; Wong, D. M.; Silman, I.; Sussman, J. L. Bivalent ligands derived from huperzine A as acetylcholinesterase inhibitors Curr. Top. Med. Chem. 2007, 7, 375-387
28. Muñoz-Torrero, D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease Curr. Med. Chem. 2008, 15, 2433-2455
29. Rampa, A.; Belluti, F.; Gobbi, S.; Bisi, A. Hybrid-based multi-target ligands for the treatment of Alzheimer's disease Curr. Top. Med. Chem. 2011, 11, 2716-2730
30. Pickhardt, M.; Gazova, Z.; von Bergen, M.; Khlistunova, I.; Wang, Y.; Hascher, A.; Mandelkow, E.-M.; Biernat, J.; Mandelkow, E. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells J. Biol. Chem. 2005, 280, 3628-3635
31. Bulic, B.; Pickhardt, M.; Schmidt, B.; Mandelkow, E.-M.; Waldmann, H.; Mandelkow, E. Development of tau aggregation inhibitors for Alzheimer's disease Angew. Chem., Int. Ed. 2009, 48, 1740-1752
32. Yang, X.; Sun, G.; Yang, C.; Wang, B. Novel rhein analogues as potential anticancer agents ChemMedChem 2011, 6, 2294-2301
33. Shi, D.-H.; Huang, W.; Li, C.; Wang, L.-T.; Wang, S.-F. Synthesis, biological evaluation and molecular modeling of aloe-emodin derivatives as new acetylcholinesterase inhibitors Bioorg. Med. Chem. 2013, 21, 1064-1073
34. Orhan, I.; Tosun, F.; Şener, B. Coumarin, anthroquinone and stilbene derivatives with anticholinesterase activity Z. Naturforsch. 2008, 63c, 366-370
35. Guo, J.-P.; Yu, S.; McGeer, P. L. Simple in vitro assay to identify amyloid-β aggregation blockers for Alzheimer's disease therapy J. Alzheimer's Dis. 2010, 19, 1359-1370
36. Camps, P.; Contreras, J.; Font-Bardia, M.; Morral, J.; Muñoz-Torrero, D.; Solans, X. Enantioselective synthesis of tacrine-huperzine A hybrids. Preparative chiral MPLC separation of their racemic mixtures and absolute configuration assignments by X-ray diffraction analysis Tetrahedron: Asymmetry 1998, 9, 835-849
37. Camps, P.; El Achab, R.; Morral, J.; Muñoz-Torrero, D.; Badia, A.; Baños, J. E.; Vivas, N. M.; Barril, X.; Orozco, M.; Luque, F. J. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease J. Med. Chem. 2000, 43, 4657-4666
38. Camps, P.; Cusack, B.; Mallender, W. D.; El Achab, R.; Morral, J.; Muñoz-Torrero, D.; Rosenberry, T. L. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for the treatment of Alzheimer's disease Mol. Pharmacol. 2000, 57, 409-417
39. Dvir, H.; Wong, D. M.; Harel, M.; Barril, X.; Orozco, M.; Luque, F. J.; Muñoz-Torrero, D.; Camps, P.; Rosenberry, T. L.; Silman, I.; Sussman, J. L. 3D Structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 Å resolution: Kinetic and molecular dynamics correlates Biochemistry 2002, 41, 2970-2981
40. Galdeano, C.; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M. V.; Relat, J.; Ratia, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Salmona, M.; Minguillón, C.; González-Muñoz, G. C.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Muñoz-Torrero, D. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases J. Med. Chem. 2012, 55, 661-669
41. Camps, P.; Formosa, X.; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Huertas, O.; Dafni, T.; Luque, F. J. Pyrano[3,2- c ]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and β -amyloid-directed anti-Alzheimer compounds J. Med. Chem. 2009, 52, 5365-5379
42. 14C]azelaic, suberic, and sebacic acids for in vivo mechanistic studies of systemic acquired resistance in plants J. Labelled Compd. Radiopharm. 2012, 55, 39-43
43. Taber, D. F.; Kong, S. Alkylation of acetonitrile J. Org. Chem. 1997, 62, 8575-8576
44. Lethesh, K. C.; Van Hecke, K.; Van Meervelt, L.; Nockemann, P.; Kirchner, B.; Zahn, S.; Parac-Vogt, T. N.; Dehaen, W.; Binnemans, K. Nitrile- functionalized pyridinium, pyrrolidinium, and piperidinium ionic liquids J. Phys. Chem. B 2011, 115, 8424-8438
45. Lane, R. M.; Potkin, S. G.; Enz, A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia Int. J. Neuropsychopharmacol. 2006, 9, 101-124
46. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-95
47. Rydberg, E. H.; Brumshtein, B.; Greenblatt, H. M.; Wong, D. M.; Shaya, D.; Williams, L. D.; Carlier, P. R.; Pang, Y.-P.; Silman, I.; Sussman, J. L. Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: binding of bis(5)-tacrine produces a dramatic rearrangement in the active site gorge J. Med. Chem. 2006, 49, 5491-5500
48. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease J. Med. Chem. 2007, 50, 6446-6449
49. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies Biochem. Pharmacol. 2003, 65, 407-416
50. Rouleau, J.; Iorga, B. I.; Guillou, C. New potent human acetylcholinesterase inhibitors in the tetracyclic triperpene series with inhibitory potency on amyloid β aggregation Eur. J. Med. Chem. 2011, 46, 2193-2205
51. Mohamed, T.; Yeung, J. C. K.; Rao, P. P. N. Development of 2-substituted- N -(naphth-1-ylmethyl) and N -benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: synthesis and biological evaluation Bioorg. Med. Chem. Lett. 2011, 21, 5881-5887
52. Bolognesi, M. L.; Bartolini, M.; Mancini, F.; Chiriano, G.; Ceccarini, L.; Rosini, M.; Milelli, A.; Tumiatti, V.; Andrisano, V.; Melchiorre, C. Bis(7)-tacrine derivatives as multitarget-directed ligands: focus on anticholinesterase and antiamyloid activities ChemMedChem 2010, 5, 1215-1220
53. Minarini, A.; Milelli, A.; Tumiatti, V.; Rosini, M.; Simoni, E.; Bolognesi, M. L.; Andrisano, V.; Bartolini, M.; Motori, E.; Angeloni, C.; Hrelia, S. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment Neuropharmacology 2012, 62, 997-1003
54. Rizzo, S.; Bisi, A.; Bartolini, M.; Mancini, F.; Belluti, F.; Gobbi, S.; Andrisano, V.; Rampa, A. Multi-target strategy to address Alzheimer's disease: design, synthesis and biological evaluation of new tacrine-based dimers Eur. J. Med. Chem. 2011, 46, 4336-4343
55. Belluti, F.; Bartolini, M.; Bottegoni, G.; Bisi, A.; Cavalli, A.; Andrisano, V.; Rampa, A. Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation Eur. J. Med. Chem. 2011, 46, 1682-1693
56. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease Angew. Chem., Int. Ed. 2007, 46, 3689-3692
57. Muñoz-Ruiz, P.; Rubio, L.; García-Palomero, E.; Dorronsoro, I.; del Monte-Millán, M.; Valenzuela, R.; Usán, P.; de Austria, C.; Bartolini, M.; Andrisano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F. J.; Medina, M.; Martínez, A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease J. Med. Chem. 2005, 48, 7223-7233
58. Bartolini, M.; Bertucci, C.; Bolognesi, M. L.; Cavalli, A.; Melchiorre, C.; Andrisano, V. Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action ChemBioChem 2007, 8, 2152-2161
59. May, P. C.; Dean, R. A.; Lowe, S. L.; Martenyi, F.; Sheehan, S. M.; Boggs, L. N.; Monk, S. A.; Mathes, B. M.; Mergott, D. J.; Watson, B. M.; Stout, S. L.; Timm, D. E.; Smith LaBell, E.; Gonzales, C. R.; Nakano, M.; Jhee, S. S.; Yen, M.; Ereshefsky, L.; Lindstrom, T. D.; Calligaro, D. O.; Cocke, P. J.; Hall, D. G.; Friedrich, S.; Citron, M.; Audia, J. E. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor J. Neurosci. 2011, 31, 16507-16516
60. Butini, S.; Brogi, S.; Novellino, E.; Campiani, G.; Ghosh, A. K.; Brindisi, M.; Gemma, S. The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors Curr. Top. Med. Chem. 2013, 13, 1787-1807
61. Galdeano, C.; Viayna, E.; Arroyo, P.; Bidon-Chanal, A.; Blas, J. R.; Muñoz-Torrero, D.; Luque, F. J. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents Curr. Pharm. Des. 2010, 16, 2818-2836
62. Fu, H.; Li, W.; Luo, J.; Lee, N. T. K.; Li, M.; Tsim, K. W. K.; Pang, Y.; Youdim, M. B. H.; Han, Y. Promising anti-Alzheimer's dimer bis(7)-tacrine reduces β-amyloid generation by directly inhibiting BACE-1 activity Biochem. Biophys. Res. Commun. 2008, 366, 631-636
63. Hanessian, S.; Yun, H.; Hou, Y.; Yang, G.; Bayrakdarian, M.; Therrien, E.; Moitessier, N.; Roggo, S.; Veenstra, S.; Tintelnot-Blomley, M.; Rondeau, J.-M.; Ostermeier, C.; Strauss, A.; Ramage, P.; Paganetti, P.; Neumann, U.; Betschart, C. Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics J. Med. Chem. 2005, 48, 5175-5190
64. Ballatore, C.; Brunden, K. R.; Piscitelli, F.; James, M. J.; Crowe, A.; Yao, Y.; Hyde, E.; Trojanowski, J. Q.; Lee, V. M.-Y.; Smith, A. B., III Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of Tau aggregation J. Med. Chem. 2010, 53, 3739-3747
65. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
66. Morphy, R.; Rankovic, Z. Designing multiple ligands-medicinal chemistry strategies and challenges Curr. Pharm. Des. 2009, 15, 587-600
67. García-Palomero, E.; Muñoz, P.; Usan, P.; Garcia, P.; De Austria, C.; Valenzuela, R.; Rubio, L.; Medina, M.; Martínez, A. Potent β-amyloid modulators Neurodegener. Dis. 2008, 5, 153-156
68. Spuch, C.; Antequera, D.; Fernandez-Bachiller, M. I.; Rodríguez-Franco, M. I.; Carro, E. A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease Neurotoxicol. Res. 2010, 17, 421-431
69. Efremov, I. V.; Vajdos, F. F.; Borzilleri, K. A.; Capetta, S.; Chen, H.; Dorff, P. H.; Dutra, J. K.; Goldstein, S. W.; Mansour, M.; McColl, A.; Noell, S.; Oborski, C. E.; O'Connell, T. N.; O'Sullivan, T. J.; Pandit, J.; Wang, H.; Wei, B.; Withka, J. M. Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design J. Med. Chem. 2012, 55, 9069-9088
70. Lu, K.; Jiang, Y.; Chen, B.; Eldemenky, E. M.; Ma, G.; Packiarajan, M.; Chandrasena, G.; White, A. D.; Jones, K. A.; Li, B.; Hong, S.-P. Strategies to lower the Pgp efflux liability in a series of potent indole azetidine MCHR1 antagonists Bioorg. Med. Chem. Lett. 2011, 21, 5310-5314
71. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232
72. Ami, D.; Natalello, A.; Lotti, M.; Doglia, S. M. Why and how protein aggregation has to be studied in vivo Microb. Cell Fact. 2013, 12, 17
73. Villar-Piqué, A.; Ventura, S. Modeling amyloids in bacteria Microb. Cell Fact. 2012, 11, 166
74. Pouplana, S.; Espargaró, A.; Galdeano, C.; Viayna, E.; Sola, I.; Ventura, S.; Muñoz-Torrero, D.; Sabate, R. Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors Curr. Med. Chem. 2014, 21, 1152-1159
75. Porat, Y.; Abramowitz, A.; Gazit, E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism Chem. Biol. Drug Des. 2006, 67, 27-37
76. Zhang, H.-Y. Same causes, same cures Biochem. Biophys. Res. Commun. 2006, 351, 578-581
77. Narlawar, R.; Pickhardt, M.; Leuchtenberger, S.; Baumann, K.; Krause, S.; Dyrks, T.; Weggen, S.; Mandelkow, E.; Schmidt, B. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease? ChemMedChem 2008, 3, 165-172
78. LaFerla, F. M. Pathways linking Aβ and tau pathologies Biochem. Soc. Trans. 2010, 38, 993-995
79. Shankar, G. M.; Walsh, D. M. Alzheimer's disease: synaptic dysfunction and Aβ Mol Neurodegener. 2009, 4, 48
80. Lacor, P. N.; Buniel, M. C.; Chang, L.; Fernandez, S. J.; Gong, Y.; Viola, K. L.; Lambert, M. P.; Velasco, P. T.; Bigio, E. H.; Finch, C. E.; Krafft, G. A.; Klein, W. L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers J. Neurosci. 2004, 24, 10191-10200
81. Walsh, D. M.; Klyubin, I.; Fadeeva, J. V.; Cullen, W. K.; Anwyl, R.; Wolfe, M. S.; Rowan, M. J.; Selkoe, D. J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo Nature 2002, 416, 535-539
82. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. Neuropathological alterations in Alzheimer disease Cold Spring Harbor Perspect. Med. 2011, 1, a006189
83. Alkondon, M.; Albuquerque, E. X.; Pereira, E. F. R. Acetylcholinesterase inhibition reveals endogenous nicotinic modulation of glutamate inputs to CA1 stratum radiatum interneurons in hippocampal slices Neurotoxicology 2013, 36, 72-81
84. Ye, L.; Qi, J. S.; Qiao, J. T. Long-term potentiation in hippocampus of rats is enhanced by endogenous acetylcholine in a way that is independent of N -methyl- d -aspartate receptors Neurosci. Lett. 2001, 300, 145-148
85. Ardiles, A. O.; Tapia-Rojas, C. C.; Mandal, M.; Alexandre, F.; Kirkwood, A.; Inestrosa, N. C.; Palacios, A. G. Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 13835-13840
86. Garcia-Alloza, M.; Robbins, E. M.; Zhang-Nunes, S. X.; Purcell, S. M.; Betensky, R. A.; Raju, S.; Prada, C.; Greenberg, S. M.; Bacskai, B. J.; Frosch, M. P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease Neurobiol. Dis. 2006, 24, 516-524
87. Silverman, R. B. The Organic Chemistry of Enzyme-Catalyzed Reactions; Academic Press: San Diego, 2000.
88. Naiki, H.; Higuchi, K.; Nakakuki, K.; Takeda, T. Kinetic analysis of amyloid fibril polymerization in vitro Lab. Invest. 1991, 65, 104-110
89. Varela-Nallar, L.; Alfaro, I. E.; Serrano, F. G.; Parodi, J.; Inestrosa, N. C. Wingless-type family member 5a (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 21164-21169
90. Inestrosa, N. C.; Carvajal, F. J.; Zolezzi, J. M.; Tapia-Rojas, C.; Serrano, F.; Karmelic, D.; Toledo, E. M.; Toro, A.; Toro, J.; Santos, M. J. Peroxisome proliferator reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease J. Alzheimer's Dis. 2013, 33, 941-959
91. Carvajal, F. J.; Zolezzi, J. M.; Tapia-Rojas, C.; Godoy, J. A.; Inestrosa, N. C. Tetrahydrohyperforin decreases cholinergic markers associated with amyloid-β plaques, 4-hydroxynonenal formation, and caspase-3 activation in AβPP/PS1 mice J. Alzheimer's Dis. 2013, 36, 99-118
92. Dinamarca, M. C.; Sagal, J. P.; Quintanilla, R. A.; Godoy, J. A.; Arrázola, M. S.; Inestrosa, N. C. Amyloid-β-acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Aβ peptide. Implications for the pathogenesis of Alzheimer's disease Mol. Neurodegener. 2010, 5, 4
93. Dvir, H.; Silman, I.; Harel, M.; Rosenberry, T. L.; Sussman, J. L. Acetylcholinesterase: from 3D structure to function Chem.-Biol. Interact. 2010, 187, 10-22
94. Morley, S. D.; Afshar, M. Validation of an empirical RNA-ligand scoring function for fast flexible docking using RiboDock J. Comput.-Aided Mol. Des. 2004, 18, 189-208
95. Schmidtke, P.; Bidon-Chanal, A.; Luque, F. J.; Barril, X. MDpocket: open source cavity detection and characterization on molecular dynamics trajectories Bioinformatics 2011, 27, 3276-3285
96. Schmidtke, P.; Barril, X. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites J. Med. Chem. 2010, 53, 5858-5867
97. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196
98. Salomon-Ferrer, R.; Goetz, A. W.; Poole, D.; Le Grand, S.; Walker, R. C. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent Particle Mesh Ewald J. Chem. Theory Comput. 2013, 9, 3878-3888
99. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Walker, R. C.; Zhang, W.; Merz, K. M.; Roberts, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Swails, J.; Goetz, A. W.; Kolossváry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Wolf, R. M.; Liu, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Cai, Q.; Ye, X.; Wang, J.; Hsieh, M.-J.; Cui, G.; Roe, D. R.; Mathews, D. H.; Seetin, M. G.; Salomon-Ferrer, R.; Sagui, C.; Babin, V.; Luchko, T.; Gusarov, S.; Kovalenko, A.; Kollman, P. A. AMBER 12; University of California: San Francisco, 2012.
100. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins 2006, 65, 712-725
101. Wang, J. M.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2005, 26, 1157-1174
102. Joung, I. S.; Cheatham, T. E. Molecular dynamics simulations of the dynamic and energetic properties of alkali and halide ions using water-model-specific ion parameters J. Phys. Chem. B 2009, 113, 13279-13290
103. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09, revision C.01; Gaussian, Inc.: Wallingford CT, 2009.
104. Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model J. Phys. Chem. 1993, 97, 10269-10280
105. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935